Form 4: Novavax CFO Kelly Reports RSU Vesting, Tax-Related Share Sale

Novavax's EVP, CFO, and Treasurer, James Patrick Kelly, reported the vesting of 43,167 Restricted Stock Units and a subsequent sale of 20,850 shares to cover tax obligations.

Summary

• James Patrick Kelly, EVP, CFO, and Treasurer of Novavax Inc., reported transactions on March 3, 2026.
• Acquired 43,167 shares of common stock at a price of $0, resulting from the vesting of Restricted Stock Units (RSUs).
• Disposed of 20,850 shares of common stock at $9.49 per share to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, Kelly directly owns 124,280 shares of common stock.
• Kelly also holds 86,333 Restricted Stock Units, which vest one-third annually over three years from March 1, 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and retention, with the tax-related sale being a standard practice rather than a discretionary divestment.

Positives

• The vesting of Restricted Stock Units indicates continued compensation and retention of a key executive.
• The acquisition of 43,167 shares at $0 reflects a gain for the executive from previously granted equity incentives.

Negatives

• The disposition of 20,850 shares, while for tax purposes, reduces the executive's direct ownership in the company.

Risks

• Future share price fluctuations could impact the value of the executive's remaining equity holdings.
• Continued employment is a condition for future RSU vesting, posing a risk to the executive's full equity realization if employment ceases.

Future Outlook

The filing indicates future vesting of the remaining 86,333 Restricted Stock Units, with one-third vesting on each of the next two anniversaries of March 1, 2024, contingent on continued employment.

Industry Context

StockSavvy.ai notes that executive equity compensation, including RSU grants and vesting, is a standard practice across the biotechnology and pharmaceutical industries, aligning executive incentives with shareholder value over the long term. Tax-related sales are common and generally not indicative of a change in sentiment.

Stakeholder Impact

• Shareholders: The vesting and tax-related sale are routine and have minimal direct impact on current share price, but reflect ongoing executive alignment through equity.
• Employees: The RSU vesting demonstrates the company's commitment to executive compensation and retention strategies.

Next Steps

• Future vesting of the remaining 86,333 Restricted Stock Units on the second and third anniversaries of March 1, 2024, subject to continued employment.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities (RSU vesting and tax-related share sale) and does not provide new fundamental information about Novavax's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are expected and do not signal a change in executive confidence or company outlook.

Keywords

Novavax, NVAX, Form 4, Insider Trading, Executive Compensation, RSU Vesting, Stock Sale, James Patrick Kelly, CFO